Amgen's Aranesp Achieves Primary Aim In MDS Trial
This article was originally published in Scrip
Amgen Inc's legacy product Aranesp (darbepoetin alfa) has met its primary goal of reducing the incidence of red blood cell transfusions in anaemic patients suffering from myelodysplastic syndrome (MDS) in a Phase III trial dubbed ARCADE, results of which will be presented at a future unspecified medical conference, the California-based company said in a statement Feb. 16.
You may also be interested in...
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.